Immunovant has been granted a patent for an anti-FcRn antibody with improved stability, binding non-competitively with IgG. The antibody reduces pathogenic autoantibodies in the blood efficiently, making it a promising treatment for autoimmune diseases. GlobalData’s report on Immunovant gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Immunovant Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Immunovant, was a key innovation area identified from patents. Immunovant's grant share as of February 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.

Anti-fcrn antibody with improved stability for autoimmune disease treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Immunovant Inc

A recently granted patent (Publication Number: US11926669B2) discloses an invention related to an anti-FcRn antibody or its antigen-binding fragment. The antibody comprises specific amino acid sequences in its light and heavy chain variable regions, as outlined in the claims. Additionally, the patent covers the use of this antibody in treating autoimmune diseases, including but not limited to autoimmune neutropenia, multiple sclerosis, rheumatoid arthritis, lupus, and various other conditions.

Furthermore, the patent details methods for producing the anti-FcRn antibody, encoding the antibody's polynucleotide, and formulating a pharmaceutical composition containing the antibody. The patent also includes specific dosing regimens and administration routes for treating autoimmune diseases in human subjects. Notably, the administering of the antibody is designed to minimize adverse effects on blood albumin levels, total cholesterol, and LDL levels in the treated individuals. This patent represents a significant advancement in the field of antibody-based therapies for autoimmune diseases, offering a targeted approach with potential benefits for patient outcomes.

To know more about GlobalData’s detailed insights on Immunovant, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies